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RR19.
A Longitudinal Comparison of Endovascular and
Open Surgical Management of Popliteal Artery Aneu-
rysms in the US Medicare Population
Todd R. Vogel, Paul L. O’Donnell, Viktor Y. Dombrovs-
kiy, Alan M. Graham. Department of Surgery, UMDNJ-
Robert Wood Johnson Medical School, New Brunswick,
NJ
Objectives: The treatment of popliteal artery aneu-
rysms has undergone significant transition from open
surgery to endovascular graft placement. Despite this
dramatic change, few longitudinal data exist evaluating
outcomes. (Methods: The Centers of Medicare & Medicaid Ser-
ices Inpatient claims (2005-2007) were queried with a
rincipal diagnosis of lower extremity artery aneurysm in
ssociation with elective CPT codes for open (OPEN) and
ndovascular (ENDO) repair of popliteal artery aneurysms.
omplications, mortality, readmission, and re-interven-
ions were evaluated.
Results: 2,962 patients were identified. The fre-
uency of endovascular interventions increased from
1.7% to 23.6% (p  .0001). The overall complication
ates after OPEN (11.3%) and ENDO (9.3%) procedures
id not differ significantly (p0.17). Cardiac, pulmo-
ary, and infectious complications were more frequent
fter OPEN whereas hemorrhagic complications oc-
urred more frequently after ENDO. No significant dif-
erences in the 30- and 90-day mortality rates were found
etween OPEN vs. ENDO. Secondary re-interventions
or ENDO were greater at both 30 days (4.6%vs.2.1%;
.001) and 90 days (11.8%vs.7.4%;p0.0007). Embolec-
omy and thrombolysis rates over time were significantly
igher after ENDO at 30 days (1.82%vs.0.46%,p.0006 and
.46%vs.0.25%,p0.0002) and 90 days (2.73%vs.0.75%,
.0002 and 3.28%vs.0.75%,p0.0002). The length of
tay (days) was greater for OPEN (4.5vs.2.5,p .0001), yet
otal hospital charges were greater for ENDO ($43,180
s.$35,540,p.0001).
Conclusions: Despite a significant increase in endovas-
ular repair of popliteal artery aneurysms in the US Medi-
are population, endovascular repair was associated with
reater re-interventions over time. Although endovascular
epair had shorter lengths of stay and is considered less
nvasive, it did not offer a mortality or cost benefit. Further
etailed analysis is needed before endovascular repair
hould be considered the treatment of choice for popliteal
neurysms.
uthor Disclosures: V. Y. Dombrovskiy: Nothing to
isclose; A. M. Graham: Nothing to disclose; P. L.
’Donnell: Nothing to disclose; T. R. Vogel: Nothing to
isclose.
R20.
ltrasound-Accelerated Thrombolysis is Superior to
atheter-Directed Thrombolysis for the Treatment of
cute Limb Ischemia
aria E. Litzendorf, Jean E. Starr, Bhagwan Satiani, Kath-
rine E. Notter. Ohio State University, Columbus, OH
Objectives: Ultrasound-accelerated thrombolysis has
ecome an alternative to traditional catheter-directed
hrombolysis for the treatment of acute limb ischemia. The
urpose of this study was to compare outcomes and hospi-
al costs for these two treatments.
Methods: A hospital record review was performed of
ll patients treated with catheter-directed thrombolysis
non-EKOS) versus ultrasound-accelerated thrombolysis
EKOS) from January 2007 through December 2009.
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Volume 53, Number 17S Abstracts 107SPatient demographics, procedural outcomes, complica-
tions, lengths of stay, and hospital economic data were
recorded.
Results: A total of 85 patients were treated. 43
underwent EKOS thrombolysis and 42 had non-EKOS
thrombolysis. Both treatment groups had similar comor-
bidities and prior vascular procedures. Total treatment
times for the EKOS group were 21.2 hours versus 56.5
hours for the non-EKOS patients (p 0.001). The
EKOS group had a higher complete thrombus dissolu-
tion rate (95.3% vs 66.7%, p0.002) and a lower thirty
day amputation rate (19.5% vs 42.9%, p0.04). There
was a significantly higher bleeding rate in the non-EKOS
group (23.8% vs 4.7%, p0.026). Length of stay on the
vascular service favored the EKOS group (5.7 vs 8.3
days, p0.027). Total procedural costs were similar for
both groups ($18,270 for EKOS vs $16,650 for non-
EKOS, p0.366).
Conclusions: Ultrasound-accelerated arterial throm-
bolysis had shorter treatment times, higher complete
thrombus dissolution rates, lower amputation and bleeding
rates, and shorter lengths of stay than patients who under-
went traditional catheter-directed thrombolysis. Despite
the favorable clinical outcome for EKOS, total procedural
costs remained similar.
Author Disclosures: M. E. Litzendorf: Nothing to dis-
close; K. E. Notter: Nothing to disclose; B. Satiani:
Nothing to disclose; J. E. Starr: Nothing to disclose.
RR21.
Early (30 Day) Vein Remodeling is Predictive of Mid-
Term Graft PatencY Following Lower Extremity By-
pass
Warren J. Gasper1, Christopher Owens1, Ji Min Kim1,
Mark A. Creager2, Marie Gerhard-Herman2, Timothy
Love2, Michael Belkin2, Michael S. Conte1. 1University of
California San Francisco, San Francisco, CA; 2Brigham and
Womens Hospital, Boston, MA
Objectives: Successful adaptation of a vein graft to an
arterial environment is incompletely understood. We
sought to investigate whether early vein graft remodeling is
predictive of subsequent patency.
Methods: A prospective longitudinal study of pa-
tients undergoing LEB with autologous vein (n98).
Preoperative blood samples were drawn for biomarkers.
At the bypass operation, a 5 cm index segment of the
graft was registered for serial lumen diameter measure-
ments (1, 3, 6, 9, and 12 months) using duplex
ultrasound.
Results: Index segment lumen diameter at 1 month
was predictive of primary graft patency (p0.013, Cox
model) with a median follow-up of 28 months. Percent
change in vein diameter from 0-1 month showed a trend
of positive correlation with primary graft patency
(p0.1). On multivariate regression, larger initial vein wiameter (p0.001), baseline high-sensitivity C-reactive
rotein (hsCRP) level (p0.007) and non-white race
p0.035) were negatively correlated with 0-1 month
raft remodeling, while statin use (p0.049) was posi-
ively correlated with remodeling. Similarly, initial diam-
ter (p0.001), hsCRP (p0.03) and non-white race
ere negatively correlated with diameter achieved at 1
onth.
Conclusions:Early remodeling of the arterialized vein,
easured from a representative mid-graft segment, appears
o predict mid-term bypass graft patency. In addition to
aseline diameter, race, inflammation (hsCRP) and statin
se are associated with early adaptive remodeling, but the
echanism for these observations are not understood.
ndex segment diameter at 1 month (by quartiles).
Quartile 1 month diameter
Percent diameter
change 0-1
months
hsCRP
(mg/L)
Primary patency
rate at 2 years
0.37 (0.34-0.39) 11% 4.0 (1.5-23.8) 39%
0.43 (0.41-0.44) 13% 5.1 (1.2-19.3) 44%
0.47 (0.47-0.5) 18% 3.3 (1.8-5.5) 69%
0.59 (0.54-0.65) 45% 2.9 (1.2-4.6) 80%
ll values are median (IQR).
uthor Disclosures: M. Belkin: Nothing to disclose;
. S. Conte: Nothing to disclose; M. A. Creager: Noth-
ng to disclose; W. J. Gasper: Nothing to disclose; M.
erhard-Herman: Nothing to disclose; J. Kim: Nothing
o disclose; T. Love: Nothing to disclose; C. Owens:
othing to disclose.
R22.
omprehensive Evaluation of Arterial Lesion Charac-
eristics and Their Impact on Long-Term Patency after
ndovascular Intervention: The Creation of a Novel
esion Severity Score For Arterial Lesions
ndrew J. Meltzer1, In-Kyong Kim1, Sikandar Z. Khan1,
atalia Egorova2, Ashley Graham1, James F. McKinsey1.
Vascular Surgery, New York-Presbyterian Hospital, New
ork, NY; 2Mount Sinai Medical Center, New York, NY
Objectives: To develop a lesion severity score(LSS) for
rterial occlusive lesions that can be used to characterize
esions for comparison and predict effectiveness of
ntervention.
Methods: Prospective data assessment with patency
etermined by clinical and duplex criteria from 2005-
009. Variables evaluated by Cox Regression (CR). CR
oefficients and Hazard Ratio used to derive risk factor
cores; these were summed to create a LSS. Correlation
etween LSS and patency performed with Kaplan-Meier
nd CR.
Results: 1848 lesions were treated in 1049 patients.
4 variables were examined; statistically significant fac-
ors were included in the final model (Table 1). Outcome
orsened with increasing LSS (Table 2).
